Topical Minoxidil-Finasteride Combination vs Minoxidil Alone: 2025 Meta-Analysis Research Summary
This is a plain-language summary of the original published research. We do not add conclusions or opinions of our own. This is not medical advice — consult a certified healthcare practitioner before making any decision.
Original research published in Frontiers in Medicine, 2025
Topical Minoxidil-Finasteride Combination vs Minoxidil Alone: 2025 Meta-Analysis Research Summary
Study conclusion
This meta-analysis of 7 randomised controlled trials found that combining topical minoxidil with topical finasteride in a mixed solution produced significantly better results than minoxidil alone for men with pattern hair loss. Hair density, hair diameter, and photographic assessment scores all improved significantly more with the combination than with minoxidil alone.
Strength of evidence
Who it applies to
Who was studied
Men with male pattern hair loss. 396 participants across 7 RCTs from 5 countries. All used topical minoxidil-finasteride combined solution (3-5% minoxidil + 0.1-0.25% finasteride) compared against topical minoxidil alone.
Who was NOT studied
Women with pattern hair loss. People using oral finasteride or oral minoxidil. People using topical finasteride without minoxidil.
What to look for when shopping
No FDA-approved topical minoxidil-finasteride combination product exists. Such products are compounded (custom-made by pharmacies). Topical finasteride carries a 2024 FDA adverse event communication. Both components are prescription-only.
What research cannot help you decide
Whether the combination is safer than oral finasteride for sexual side effects. What the optimal concentrations of each component are. These require a prescribing doctor.
Key findings
- Combination topical minoxidil-finasteride produced significantly more hair density improvement than minoxidil alone (mean difference 9.22 hairs per cm2)
- Hair diameter also improved more with the combination than with minoxidil alone (mean difference 2.26 micrometres)
- Photographic assessment showed stronger improvement with combination therapy
- Low heterogeneity across the main outcome — results were consistent across all 7 trials
- No FDA-approved topical minoxidil-finasteride product exists — all products are compounded and off-label
What this study does not show
- 1.Whether the combination reduces sexual side effects compared to oral finasteride. The trials were not powered to assess this.
- 2.What the optimal concentrations of each component are.
- 3.How the combination performs in women. All included trials studied men only.
- 4.Long-term effects beyond 6 months.
Limitations
- 1.No FDA-approved topical minoxidil-finasteride product exists. All products are compounded and off-label.
- 2.Topical finasteride carries a 2024 FDA adverse event communication.
- 3.Individual trial sample sizes ranged from 22 to 164 participants — relatively small.
- 4.Most trials ran 3-6 months. Long-term data is absent.
- 5.Dose variations across trials (3-5% minoxidil, 0.1-0.25% finasteride) limit precision.
Used in these articles
Links added as fact-checks and articles citing this study are published.